Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors:: a [35S]GTPγS binding study

被引:207
作者
Newman-Tancredi, A [1 ]
Gavaudan, S [1 ]
Conte, C [1 ]
Chaput, C [1 ]
Touzard, M [1 ]
Verrièle, L [1 ]
Audinot, V [1 ]
Millan, MJ [1 ]
机构
[1] Inst Rech Servier, Dept Psychopharmacol, F-78290 Paris, France
关键词
5-HT1A receptor; S-35]GTP gamma S binding; schizophrenia; clozapine; ziprasidone; risperidone;
D O I
10.1016/S0014-2999(98)00483-X
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Recombinant human (h) 5-HT1A receptor-mediated G-protein activation was characterised in membranes of transfected Chinese hamster ovary (CHO) cells by use of guanosine-5'-O-(3-[S-35]thio)-triphosphate ([S-35]GTP gamma S binding). The potency and efficacy of 21 5-HT receptor agonists and antagonists was determined. The agonists, 5-CT (carboxamidotryptamine) and flesinoxan displayed high affinity (subnanomolar K-i values) and high efficacy (E-max > 90%, relative to 5-HT = 100%). In contrast, ipsapirone, zalospirone and buspirone displayed partial agonist activity. EC(50)s for agonist stimulation of [S-35]GTP gamma S binding correlated well with K-i values from competition binding (r = +0.99). Among the compounds tested for antagonist activity, methiothepin and (+)butaclamol exhibited 'inverse agonist' behaviour, inhibiting basal [S-35]GTP gamma S binding. The actions of 17 antipsychotic agents were investigated. Clozapine and several putatively 'atypical' antipsychotic agents, including ziprasidone, quetiapine and tiospirone, exhibited partial agonist activity and marked affinity at h5-HT1A receptors, similar to their affinity at hD(2) dopamine receptors. In contrast, risperidone and sertindole displayed low affinity at h5-HT1A receptors and behaved as 'neutral' antagonists, inhibiting 5-HT-stimulated [S-35]GTP gamma S binding. Likewise the 'typical' neuroleptics, haloperidol, pimozide, raclopride and chlorpromazine exhibited relatively low affinity and 'neutral' antagonist activity at h5-HT1A receptors with K-i values which correlated with their respective K-i values. The present data show that (i) [S-35]GTP gamma S binding is an effective method to evaluate the efficacy and potency of agonists and antagonists at recombinant human 5-HT1A receptors. (ii) Like clozapine, several putatively 'atypical' antipsychotic drugs display balanced serotonin h5-HT1A/dopamine hD(2) receptor affinity and partial agonist activity at hS-HT1A receptors. (iii) Several 'typical' and some putatively 'atypical' antipsychotic agents displayed antagonist properties at h5-HT1A sites with generally much lower affinity than at hD(2) dopamine receptors. It is suggested that agonist activity at 5-HT1A receptors may be of utility for certain antipsychotic agents. (C) 1998 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:245 / 256
页数:12
相关论文
共 81 条
[1]   Prevention by (+/-)-8-hydroxy-2-(di-n-propylamino)tetra of both catalepsy and the rises in rat striatal dopamine metabolism caused by haloperidol [J].
Andersen, HL ;
Kilpatrick, IC .
BRITISH JOURNAL OF PHARMACOLOGY, 1996, 118 (02) :421-427
[2]   THE 5-HT1A RECEPTOR ANTAGONIST (S)-UH-301 BLOCKS THE (R)-8-OH-DPAT-INDUCED INHIBITION OF SEROTONERGIC DORSAL RAPHE CELL FIRING IN THE RAT [J].
ARBORELIUS, L ;
HOOK, BB ;
HACKSELL, U ;
SVENSSON, TH .
JOURNAL OF NEURAL TRANSMISSION-GENERAL SECTION, 1994, 96 (03) :179-186
[3]  
AUDINOT V, 1995, EUR NEUROPSYCHOPHARM, V5, P4
[4]  
Baldessarini R., 1996, GOODMAN GILMANS PHAR, P399
[5]  
BARKER EL, 1994, J BIOL CHEM, V269, P11687
[6]   5-HT1A receptors are not involved in clozapine's lack of cataleptogenic potential [J].
Bartoszyk, GD ;
Roos, C ;
Ziegler, H .
NEUROPHARMACOLOGY, 1996, 35 (11) :1645-1646
[7]  
BJORK L, 1991, J PHARMACOL EXP THER, V258, P58
[8]   MOLECULAR-BIOLOGY OF 5-HT RECEPTORS [J].
BOESS, FG ;
MARTIN, IL .
NEUROPHARMACOLOGY, 1994, 33 (3-4) :275-317
[9]   Serotonin receptors in cognitive behaviors [J].
Buhot, MC .
CURRENT OPINION IN NEUROBIOLOGY, 1997, 7 (02) :243-254
[10]   [H-3]WAY-100635 for 5-HT1A receptor autoradiography in human brain: A comparison with [H-3]8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia [J].
Burnet, PWJ ;
Eastwood, SL ;
Harrison, PJ .
NEUROCHEMISTRY INTERNATIONAL, 1997, 30 (06) :565-574